48
Introduction 49 Globally, increasing numbers of infections are caused by bacteria resistant to current 50 antibiotics.
[1] As there is a lack of new antibiotics in development, the revival of older 51 drugs with distinct methods of action has been proposed as a short-term solution.
[2] 52 One such drug is fosfomycin, a cell wall inhibitor discovered in 1969, with a novel 53 mode of action and broad spectrum activity. [3] Fosfomycin is a phosphonic-acid 54 derivative which enters bacterial cells by active transport. In Enterobacteriaceae, 55 fosfomycin is taken up by mimicking the natural substrates of two nutrient transport 56 uptake systems, the constitutively functional l-α-glycerol-3-phosphate transporter, 57 GlpT, and the hexose-uptake system, UhpT, which is inducible in the presence of [8] This unique mechanism of action allows a broad-spectrum of activity against 67 both Gram-positive and Gram-negative bacteria. As fosfomycin acts prior in the 68 biosynthesis pathway to other cell wall inhibitors β-lactams and glycopeptides it is not 69 inhibited by resistance determinants which act against these drugs. Therefore, 5 between 2012 and 2013; [25] [25] and a further increase to 2,400 prescriptions in 117 2014. [26] 118 Renewed interest in fosfomycin has been for treatment of MDR organisms causing 119 UTIs where oral therapy choices may be limited. Considering these factors and the 120 possibility of introducing fosfomycin preparations into our formulary, the first aim of 121 this study was to determine the proportion of organisms isolated from UTIs showing 122 resistance to fosfomycin. In doing so the various methods of measuring susceptibility 123 to fosfomycin in the laboratory were compared and their relative merits considered. 124 The second aim was to investigate mechanisms of fosfomycin resistance. interpretations. Due to the semi-confluent nature of the growth in these regions they 204 were not included in the zone of inhibition when reading the strips (Table 1) . 205 Investigation of fosfomycin MICs using modified agar dilution 206 To further explore the differing growth phenotypes when using E-tests, a modified 207 agar dilution method was used whereby colonies were streaked on agar containing in several different E. coli sequence types (6 different STs were seen in the 8 resistant 219 isolates, ST131 was the only ST seen more than once) indicating that resistance was 220 not distributed due to clonal expansion of one strain ( Figure 1 and Table 2 ). The E. 221 coli sequence types found in this study include those previously reported as common 222 in UTI isolates in the UK; ST69, 73, 95 and 131.
[33] 223 Each of the ten isolates were further characterised by investigating their antibiogram, 224 determined from their susceptibility profile to antimicrobials used in the treatment of 225 UTIs; and by interrogating WGS for genes and mutations known to confer 226 antimicrobial resistance (Table 2) . Ampicillin resistance was detected in 8/10 isolates, 227 accompanied with the in-silico detection of blaTEM-1B. Trimethoprim resistance in 5/10 228 isolates corresponded with the detection of a dfrA gene and with either sul1 or sul2. 229 Aminoglycoside resistance genes were identified in five of the isolates where in one 230 ST131 isolate, the presence of aac(3)-IId and a gyrA mutation corresponded to 231 gentamicin and ciprofloxacin resistance respectively. 232 The in-silico analysis also showed the presence of many common 233 Enterobacteriaceae plasmid replicons including those of incompatibility group, IncF, 234 IncQ, IncX1, IncB/O/K/Z and plasmids from the group Col and Col156. Using CARD, 235 Resfinder and manual searches, no fos-like genes were detected in any of the strains, 236 suggesting an absence of known plasmid based transferrable fosfomycin resistance 237 genes in the resistant isolates.
238 239 For each of the ten sequenced isolates, amino-acid changes or mutations in known 240 fosfomycin resistance genes murA, glpT, uhpT, uhpA, ptsI and cyaA were identified 241 from the WGS using E. coli MG1655 as a reference ( definitions; a prevalence more in line with findings of previous studies both globally 288 and within the UK. or by community pharmacists in this area, thereforepatient exposure to the drug is 295 likely to have been low, and a 1.3% rate of resistance is likely to reflect spontaneous 296 mutants which are in the wider population of E. coli. Given the reports of fosfomycin 297 resistance incurring a significant fitness cost this level may be higher than expected 298 given the probable lack of direct selection in this population. 299 In this study, micro-broth dilution was the most useful method for differentiating 300 resistant and susceptible isolates, others have found disc-diffusion assays such as isolates respectively. ST121 strain EC958 was used as a reference.
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